Core Viewpoint - Novartis has launched its innovative drug, Noreida® (Acrylamide Hydrochloride Tablets), on JD Health, marking a significant advancement in the treatment of IgA nephropathy in adult patients in China [1][2]. Group 1: Product Launch and Significance - Noreida® is the first approved non-immunotherapy for reducing the risk of rapid disease progression in adult patients with IgA nephropathy in China [1]. - It is currently the only high-selective endothelin A (ETA) receptor antagonist for this indication in the country [1]. - The drug fills a gap in non-hormonal foundational treatments for this condition, providing a new option for clinicians to manage the disease alongside existing standard treatments [2]. Group 2: Market and Patient Impact - IgA nephropathy is a common primary glomerular disease prevalent among young adults in China, particularly those aged 20 to 30 [1]. - If not effectively controlled, approximately 50% of patients with persistent proteinuria may progress to renal failure within 10 to 20 years post-diagnosis, necessitating lifelong dialysis or kidney transplantation [1]. - JD Health aims to leverage its supply chain capabilities and professional pharmacist services to ensure that innovative drugs like Noreida® reach patients more quickly and effectively across the country [1]. Group 3: Future Directions - JD Health plans to deepen its collaboration with leading global pharmaceutical companies like Novartis to introduce cutting-edge treatment options and focus on comprehensive digital health management solutions for chronic diseases, including kidney diseases [2]. - This strategy aims to enhance the quality of life for patients with kidney diseases and a broader population suffering from chronic conditions [2].

Core Insights - The National Medical Products Administration announced a complete ban on the production of mercury thermometers and sphygmomanometers starting January 1, 2026, leading to a significant market response [1] - The transition from mercury-based devices has been planned since China joined the Minamata Convention on Mercury in 2017, with a clear roadmap for phasing out these products [1] - The sales of electronic thermometers and blood pressure monitors have surged, with electronic thermometer sales increasing over 100% year-on-year and electronic blood pressure monitors up by 50% [1] Market Trends - The search volume for thermometers on JD Health has significantly increased in the past week, indicating a shift in consumer behavior towards safer and smarter home monitoring solutions [1] - Among the alternatives to mercury thermometers, non-mercury glass thermometers, ear thermometers, and forehead thermometers have emerged as the three main categories [1] - Non-mercury glass thermometers cater to traditional users who prioritize safety and cost-effectiveness, while multifunctional ear thermometers are favored by families with infants for their quick measurement capabilities [1] - Forehead thermometers are preferred for their non-contact and high-efficiency features, appealing to users focused on convenience and public health scenarios [1] Product Innovations - Omron launched a new ear thermometer on JD Health, featuring a no-ear-cap design, 1-second measurement, and high fever alerts, quickly gaining market attention [2] - JD Health offers services such as 211 same-day delivery and a 180-day exchange policy for electronic thermometers, addressing consumer needs during peak flu seasons [2] - The policy-driven upgrade trend in health monitoring devices reflects an increase in public health awareness and indicates a shift towards more professional and intelligent home health monitoring solutions [2] - JD Health aims to leverage data insights, product supply, and service innovation to support the development of a more secure and intelligent family health management ecosystem [2]

Core Insights - The National Medical Products Administration announced a ban on the production of mercury thermometers and sphygmomanometers starting January 1, 2026, leading to a significant increase in demand for alternative health monitoring devices [1][4] - The market has seen a surge in electronic thermometer sales, with a year-on-year increase of over 100%, and electronic blood pressure monitors growing by 50% [1] - The transition away from mercury devices has been planned since China joined the Minamata Convention on Mercury in 2017, allowing for a gradual phase-out and providing consumers with ample time to adapt [1] Market Trends - The search volume for thermometers on JD Health has surged, indicating a shift towards safer and smarter home monitoring solutions [1] - Among the alternatives to mercury thermometers, non-mercury glass thermometers, ear thermometers, and forehead thermometers have emerged as the three main categories [1] - Non-mercury glass thermometers cater to traditional users who prioritize safety and cost-effectiveness, while multifunctional ear thermometers are favored by families with infants for their quick measurement capabilities [1] Product Launches and Services - Omron's new ear thermometer was launched on JD Health, featuring a no-ear-cap design, 1-second measurement, and high fever alerts, quickly gaining market attention [2] - JD Health offers various services for electronic thermometers, including same-day delivery and a 180-day exchange policy for PLUS members, addressing consumer needs during flu season [2] Industry Outlook - The policy-driven upgrade in health monitoring devices reflects an increase in public health awareness and indicates a trend towards professional and intelligent home health monitoring solutions [4] - JD Health is positioned as a key player in observing health consumption trends and aims to enhance the ecosystem of home health management through data insights and service innovations [4]

Group 1 - Zoetis launched its classic pet antibiotic, Synulox, exclusively on JD Health, aiming to enhance the accessibility and standardization of pet infection medications [1] - By the end of 2024, the number of urban dogs and cats in China is expected to exceed 120 million, with annual medical spending by pet owners increasing by 21.3% year-on-year [3] - Over 68% of pet owners prefer original drugs with international clinical validation, indicating a growing concern for the safety, efficacy, and traceability of medications [3] Group 2 - The "Pet Infection Center," co-founded by JD Health and Zoetis, focuses on educating pet owners about infectious diseases, which are among the most common health issues for pets [4] - The center will provide authoritative, convenient, and scientific health solutions, leveraging Zoetis's research and clinical experience alongside JD Health's digital service capabilities [5] - JD Health is committed to building a rational medication ecosystem for pets and promoting scientific pet care concepts, while continuing to collaborate with top global animal health companies [7]

今年9月份-10月份，结合"世界心脏日"和"世界精神卫生日"两大疾病日，京东健康携手武汉协和医院、武汉大学人民医 院、武汉市精神卫生中心及知名艺术家、顶级专家，在武汉江滩打造长达13天的"心迷艺术展"。展览突破传统健康科普模式， 打造头部医院、平台、艺术家跨界合作科普创新全新范式，兼顾医学科普的专业性、可参与性及覆盖度、传播度，树立身心健 康科普行业标杆。 本报讯 （记者袁传玺） 12月5日，2025首届健康科技与科普大会在海口举行。大会由中国科技新闻学会、海南省医学学术交流管理中心指导，中 国科技新闻学会健康传播专委会、北京陈菊梅公益基金会主办，海南省科学技术协会、文昌市人民政府、海南省医学会支持， 旨在搭建健康科技与科普融合发展的国家级交流平台，推动健康科普高质量发展。 在本次大会上，京东健康"心迷艺术展"获得大会年度优秀科普传播作品评选"最佳创作作品"奖。"心迷艺术展"通过"医院 +平台+艺术家"跨界联动进行健康科普，将专业医学知识转化为公众语言，线上线下共覆盖超5.4亿人次，以艺术疗愈推动心脏 及心理健康公益普及。 未来，京东健康将携手广大合作伙伴，持续探索更多元丰富的健康科普形式，直击健康痛点、引发 ...

在本次大会上，京东健康"心迷艺术展"获得大会年度优秀科普传播作品评选"最佳创作作品"奖。"心迷 艺术展"通过"医院+平台+艺术家"跨界联动进行健康科普，将专业医学知识转化为公众语言，线上线下 共覆盖超5.4亿人次，以艺术疗愈推动心脏及心理健康公益普及。 12月5日，2025首届健康科技与科普大会在海口举行。大会由中国科技新闻学会、海南省医学学术交流 管理中心指导，中国科技新闻学会健康传播专委会、北京陈菊梅公益基金会主办，海南省科学技术协 会、文昌市人民政府、海南省医学会支持，旨在搭建健康科技与科普融合发展的国家级交流平台，推动 健康科普高质量发展。 今年9月-10月，结合"世界心脏日"和"世界精神卫生日"两大疾病日，京东健康携手武汉协和医院、武汉 大学人民医院、武汉市精神卫生中心及知名艺术家、顶级专家，在武汉江滩打造长达13天的"心迷艺术 展"。展览突破传统健康科普模式，打造头部医院、平台、艺术家跨界合作科普创新全新范式，兼顾医 学科普的专业性、可参与性及覆盖度、传播度，树立身心健康科普行业标杆。 作为京东健康在公众健康科普领域的创新尝试，"心迷艺术展"设置心脏、心理两大展览，通过艺术装 置、互动科技与心理疗 ...

Group 1 - The core viewpoint of the article is that JD Health is expected to achieve significant revenue and profit growth in 2025, with forecasts indicating a revenue range of 70.823 to 71.498 billion yuan, representing a year-on-year growth of 21.8% to 22.9% [1][8] - The expected net profit for JD Health in 2025 is projected to be between 4.416 to 5.261 billion yuan, showing a year-on-year increase of 6.1% to 26.4% [1][8] - The adjusted net profit is anticipated to be in the range of 5.665 to 6.342 billion yuan, reflecting a growth of 18.2% to 32.3% year-on-year [1][8] Group 2 - According to Haitong International Securities, JD Health's Q3 2025 performance showed strong growth, with revenue reaching 17.12 billion yuan, a year-on-year increase of 28.7%, and net profit of 1.84 billion yuan, up 97.2% [5][11] - The company has raised its full-year guidance, expecting a revenue growth of approximately 22.0% and an adjusted profit of around 6.20 billion yuan [5][11] - The growth is attributed to high performance in the pharmaceutical category and advertising business, as well as effective marketing investments [5][11] Group 3 - Minsheng Securities reported that JD Health's Q3 2025 revenue was 17.12 billion yuan, with operating profit and Non-IFRS profit increasing by 125.3% and 42.4% year-on-year, respectively [6][12] - The company has made significant progress in expanding online medical insurance payments, with coverage reaching nearly 200 million people and over 150,000 merchants on the platform [6][12] - JD Health has signed strategic cooperation agreements with several well-known pharmaceutical companies to strengthen its position in the high-end pharmaceutical supply chain [6][12]

本报讯 （记者袁传玺）近期，第五届中国医药数字营销论坛在北京举行，超过300位药企嘉宾、知名医 生、学者汇聚，探讨数字化背景下医药数字营销的发展新机遇、新挑战与新路径，共同为医药行业高质 量发展注入新动能。 京东健康医药业务负责人表示，在AI应用赋能医疗健康行业的浪潮中，京东健康携手行业合作伙伴， 在深度服务患者、创新营销实践的道路上迈出了更坚实的步伐。历经五年沉淀，在医药数字营销的规模 和独特价值方面，京东健康交出一份亮眼的答卷。 （编辑 何帆） 此前，京东健康与药企的合作主要围绕线上生意增长展开。京东健康医药业务数字营销负责人介绍，在 AI应用重塑行业格局的当下，随着行业需求变化与自身能力沉淀，京东健康进一步延伸服务边界，将 渠道覆盖从单一线上场景拓展至院外市场、药店零售市场等多元领域，构建起"全域覆盖、全链路赋 能"的服务体系，助力药企打破增长局限，挖掘更多市场增量空间。 本次京东健康数字营销解决方案的升级将为药企带来了显著便利。过去，药企若想布局线上渠道、院外 市场、药店零售市场，需分别与不同渠道方对接，面临"多对多"的复杂合作困境，不仅沟通成本高，资 源整合难度也较大。如今，京东健康通过能力整合，打 ...

Core Insights - The first Health Technology and Science Popularization Conference was held in Haikou, focusing on the theme "AI Leading a New Era of Health Science Popularization" [1] - JD Health's exploration of AI in health science popularization was highlighted, showcasing the latest developments in its "AI Jingyi" model product system [1] Group 1: AI and Health Science Popularization - JD Health's "Jingyi Qianxun" medical model integrates authoritative clinical guidelines, real-time medical literature, and vast real-world data to create a dynamic evidence database [3] - The AI doctor "Daiwei" has achieved a satisfaction rate of 98%, serving as a crucial link between users and professional medical services [3] - "Daiwei" has optimized its capabilities in traditional Chinese medicine, providing personalized health guidance based on user characteristics and symptoms [3] Group 2: AI Jingyi Product System - The "AI Jingyi" product system, launched in early 2025, is the first AI health service matrix combining AI doctors and expert doctor agents [4] - JD Health's initiatives in health science popularization include live broadcasts, short videos, and interactive Q&A, with over 1.5 billion views and more than 300 million Q&A interactions since 2025 [4] - The transition from standardized output to personalized customization in health science popularization is facilitated by the "Jingyi Qianxun" medical model [4] Group 3: Recognition and Awards - The "Heart Maze Art Exhibition," created by JD Health in collaboration with various institutions, won the "Best Creative Work" award at the conference for its innovative approach to health education [5] - The conference served as a high-level exchange platform for the integration of health technology and science popularization, providing a model for AI-enabled health education [7]

Core Insights - Health consumption is evolving from an optional demand to a basic necessity in daily life, driven by proactive health investment rather than reactive measures to illness [1] - The aging population and increased health awareness among younger generations are leading to a heightened perception of health risks, prompting consumers to seek stability and control over their health [1] Group 1: Key Trends in Health Consumption - Trend 1: Health products are transitioning from being age-specific to essential for all ages, reshaping dietary structures across demographics, with a significant focus on nutritional supplements [2] - Trend 2: Adult health consumption is diversifying, with notable growth in bone health products and a rising interest in nutritional supplements among younger consumers [3] - Trend 3: Male health awareness is increasing, with a significant portion of liver health product consumers being men aged 31-45, and a notable rise in health check-up services [4] Group 2: Consumer Behavior and Preferences - Consumers are increasingly focused on product ingredients and efficacy, with a shift towards addressing sub-health issues like obesity and sleep disorders, leading to a surge in demand for related products [4] - The popularity of pain relief products and physical therapy devices reflects the growing need for solutions to workplace fatigue and physical discomfort [5] - The demand for professional medical devices and home care services is rising, driven by an aging population and chronic disease management needs [5][6] Group 3: Emotional and Experiential Aspects of Health Products - There is a growing trend for health products to not only meet health needs but also provide emotional satisfaction and sensory enjoyment, particularly among younger consumers [9] - Health foods are breaking the stereotype of being unappetizing, with products that enhance taste and visual appeal gaining popularity [10] - The rise of intimacy-related health products indicates a societal shift towards recognizing the importance of sexual health and emotional well-being [12] Group 4: Market Insights and Data - JD Health has released a health consumption trend report based on real consumer data, highlighting the top health products and trends for 2025, reflecting collective consumer choices [12][13] - The report emphasizes the importance of data-driven insights in guiding consumers towards rational and effective health investments [13]